This study went on to demonstrate that co-treatment of EGFR-mutant NSCLC cell lines with osimertinib plus XAV939, a tankyrase inhibitor that indirectly inhibits YAP signalling, reduced both the abundance of dormant cells as well as the regrowth of cells following washout. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.